79 related articles for article (PubMed ID: 21300504)
1. Evaluation of contrast medium enhancement and [(18)F]-FDG uptake of liver metastasis in PET/CT prior to therapy.
Hundt W; la Fougère C; Vogtmann J; Steinbach S; Burbelko M; Tiling R
Eur J Radiol; 2012 Apr; 81(4):652-7. PubMed ID: 21300504
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
3. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
4. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
[TBL] [Abstract][Full Text] [Related]
5. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
6. Standardized uptake values of uterine leiomyoma with 18F-FDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI.
Kitajima K; Murakami K; Yamasaki E; Kaji Y; Sugimura K
Ann Nucl Med; 2008 Jul; 22(6):505-12. PubMed ID: 18670857
[TBL] [Abstract][Full Text] [Related]
7. The influence of different contrast medium concentrations and injection protocols on quantitative and clinical assessment of FDG-PET/CT in lung cancer.
Verburg FA; Kuhl CK; Pietsch H; Palmowski M; Mottaghy FM; Behrendt FF
Eur J Radiol; 2013 Oct; 82(10):e617-22. PubMed ID: 23880426
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
[TBL] [Abstract][Full Text] [Related]
9. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
Imbriaco M; Caprio MG; Limite G; Pace L; De Falco T; Capuano E; Salvatore M
AJR Am J Roentgenol; 2008 Nov; 191(5):1323-30. PubMed ID: 18941064
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of a breath-holding acquisition method in PET/CT for pulmonary lesions.
Yamaguchi T; Ueda O; Hara H; Sakai H; Kida T; Suzuki K; Adachi S; Ishii K
Ann Nucl Med; 2009 Jan; 23(1):65-71. PubMed ID: 19205840
[TBL] [Abstract][Full Text] [Related]
11. Computer-aided detection (CAD) and assessment of malignant lesions in the liver and lung using a novel PET/CT software tool: initial results.
Hahn S; Heusner T; Zhou X; Zhan Y; Peng Z; Hamami M; Forsting M; Bockisch A; Antoch G
Rofo; 2010 Mar; 182(3):243-7. PubMed ID: 19859858
[TBL] [Abstract][Full Text] [Related]
12. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS
J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT for staging of penile cancer.
Scher B; Seitz M; Reiser M; Hungerhuber E; Hahn K; Tiling R; Herzog P; Reiser M; Schneede P; Dresel S
J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528
[TBL] [Abstract][Full Text] [Related]
16. Body surface area adapted iopromide 300 mg/ml versus 370 mg/ml contrast medium injection protocol: influence on quantitative and clinical assessment in combined PET/CT.
Verburg FA; Apitzsch J; Lensing C; Kuhl CK; Pietsch H; Mottaghy FM; Behrendt FF
Eur J Radiol; 2013 Dec; 82(12):2348-52. PubMed ID: 24113432
[TBL] [Abstract][Full Text] [Related]
17. Role of IV iodinated contrast material in 18F-FDG PET/CT of liver metastases.
Badiee S; Franc BL; Webb EM; Chu B; Hawkins RA; Coakley F; Singer L
AJR Am J Roentgenol; 2008 Nov; 191(5):1436-9. PubMed ID: 18941082
[TBL] [Abstract][Full Text] [Related]
18. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules.
Ohno Y; Koyama H; Takenaka D; Nogami M; Maniwa Y; Nishimura Y; Ohbayashi C; Sugimura K
J Magn Reson Imaging; 2008 Jun; 27(6):1284-95. PubMed ID: 18504748
[TBL] [Abstract][Full Text] [Related]
19. Correlations between SUVmax and expression of GLUT1 and growth factors inducing lymphangiogenesis.
Tian M; Yu L; Zhang Y; Gao X
Acad Radiol; 2012 Apr; 19(4):420-6. PubMed ID: 22444673
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
